Fritz Rieger

Model Building in Organizational/Cross-Cultural Research: The Need for Multiple Methods, Indices, and Cultures

ologies in cross-cultural management. These studies were part of a larger research project whose primary goal was to develop a model relating societal culture, organizational strategy, and organizational performance. Study 1 consisted of field research on nine international airlines representing five different types of societal culture. l The primary data-collection methods were unobtrusive observations and interviews with key personnel. Study 2 was essentially archival research, using the published statistics and performance records of a sample of 32 international airlines, 8 of which were also included in the field study.2 The overriding objectives in terms of building a model were to ensure that it was grounded in reality and that it was generally applicable across a variety of societies. The rationale for adopting a multimethod approach was to attempt to achieve convergence through a process of triangulation. In this way it would be

The Influence of Societal Culture on Corporate Culture, Business Strategy, and Performance in the International Airline Industry

Culture is defined as the agreed upon set of values, norms, and behaviors shared by the members of a particular social group (Segali, 1979; see also Adler, Doktor, and Redding, Chapter 2). Organizations exist in at least three different types of cultures: societal, industry, and corporate. The purpose of this study is to examine the influence of these cultures on the operating strategies and policies of international airlines.

Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective

Familial hypercholesterolaemia (FH) is an autosomal-dominant disorder associated with high low-density lipoprotein cholesterol (LDL-C). Left untreated, 50% of men with FH will develop coronary heart disease by the age of 50 and 30% of women by the age 60 [1,2]. It is estimated that the prevalence may be as high as one in 250 people, with most undiagnosed. This article explores the development of advocacy in FH patient organisations, citing examples from Canada, the Netherlands, Spain, the US and the UK as well as the pan-European patient organisation, FH Europe. The article demonstrates that for patient advocacy, the link with medical and scientific expertise is essential to ensure that advocacy for familial hypercholesterolaemia is well-founded and credible and that patient associations are prepared to take a long-term view on achieving improvements in identification and treatment.